UnknownPhase 1

Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03)

China6 participantsStarted 2023-01-10

Plain-language summary

The primary objective of this study is to evaluate the safety of Neo-T in combination with anti-PD1 in patients with solid tumors. The secondary objective of this study is to evaluate preliminarily the effect of Neo-T in combination with anti-PD1 in patients with solid tumors.

Who can participate

Age range

18 Years – 75 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Greater than or equal to 18 years of age and less than or equal to 75 years of age; all genders.
. Advanced solid tumors including but not limited to some high frequency somatic mutations,such as melanoma,driver mutation-negative non-small cell lung cancer.
. Advanced solid tumors patients who are HLA - A0201 /A1101/A2402 subtypes.
. Measurable solid tumors with at least one lesion that is resectable or tumor biopsies for DNA extraction.
. Patients who failed or were intolerant to standard treatment.
. Possess venous access for mononuclear cell collection or intravenous blood collection.
. Patients (or their legal representatives) who are able to understand and sign the Informed Consent Form and willing to sign a durable power of attorney.
. Clinical performance status of ECOG is 0 or 1.

Exclusion criteria

. Pregnant or lactating women.
. History of severe immediate hypersensitivity reaction to Neo-T and any of the agents used in this study.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Number of participants with adverse events as assessed by CTCAE v5.0.

Timeframe: one month

Trial details

NCT IDNCT05798533

SponsorBGI, China

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-09

Contact for this trial

Jian Zhang, Doctor

021-64175590 syner2000@163.com

View on ClinicalTrials.gov More Solid Tumor trials